Navigation Links
Pharmaceutical Industry Veteran is Appointed CMO at Kinex Pharmaceuticals

BUFFALO, N.Y., Feb. 25 /PRNewswire/ -- Kinex Pharmaceuticals has appointed Rudolf Kwan, MD, as Chief Medical Officer.  

Dr. Kwan has had a successful career in the pharmaceutical industry and brings to Kinex over twenty years of experience in clinical operations.  Most recently he served dual roles at Schering Plough (SP) as Vice President and Regional Head of Asia Pacific Global Clinical Operations and Vice President of Global Clinical Development, CNS.

In the clinical operations position, Dr. Kwan successfully recruited Heads of Clinical Operations for China, South East Asia, Australia, Taiwan and South Korea and set up the infrastructure to conduct global clinical trials in Asia Pacific.  

As Vice President of Global Clinical Development, CNS, Dr. Kwan was responsible for the clinical development of all SP central nervous system drugs, globally. Major achievements included developing and executing a bioequivalence registration strategy for a new formulation of Temodol, for glioblastoma, which led to a simultaneous global registration.  He also designed and executed multiple phase 2 development programs.

Earlier at Schering Plough, Dr. Kwan held various clinical operation positions with increasing responsibility.  He held similar positions at Chiron Corporation and at Smith Kline Beecham.

Dr. Kwan obtained an MD degree in Hong Kong and did subsequent training in England.  He has served as Chair of the Data Monitoring and Safety Board for the National Institute on Deafness and other Communication Disorders for trials on Celecoxib as an adjunct to surgery for Recurrent Respiratory Papillomatosis. Currently, he is a member and Chair, of the Data Monitoring and Safety Board and Protocol Review Board for the Clinical Trial Network of the National Institute on Drug Abuse (NIDA) of the National Institute of Health.  He is also a member of several advisory panels and grant review panels for NIDA.

"Kinex Pharmaceuticals is extremely pleased to announce that Dr. Rudolf Kwan is joining us as Chief Medical Officer.  He brings with him a distinguished career of achievements in clinical operations in the pharmaceutical industry," said Dr. Allen Barnett, CEO of Kinex.  

At Kinex Pharmaceuticals, Dr. Kwan will be responsible for the design and execution of the Company's clinical development programs.  In 2010, Kinex will be launching several Phase 2 studies in oncology for KX2-391 as well as a Phase 1 trial in brain cancer for KX2-361.  "Dr. Kwan's appointment comes at a critical point in our Company's development as we transition from a drug discovery company to a development company with multiple compounds in clinical development," said Dr. Barnett.

About Kinex Pharmaceuticals

Kinex is a Buffalo, NY based, privately held biopharmaceutical company committed to the discovery and development of novel therapeutics. The Company's platform technologies, Mimetica™ and Opal™, provide unique insight into the design and synthesis of target-based small molecule inhibitors that selectively act on proteins that play key roles in cancer and immuno-inflammatory diseases.

KX2-391 is currently being studied in a Phase 2 clinical trial in prostate cancer patients; additional Phase 2 oncology studies will commence later in 2010. KX2-361 is being developed for brain cancer; an IND is expected during the 4th quarter of 2010. In addition, Kinex is developing several other new product candidates that inhibit key immuno-inflammatory pathways.

For more information, visit

SOURCE Kinex Pharmaceuticals

Back to top



SOURCE Kinex Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
2. Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009
3. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results
4. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
5. Jazz Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on March 3, 2010
6. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
7. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
8. Innovative University of Cincinnati Program Trains Next Generation of Pharmaceutical Professionals
9. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
10. Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
11. Ritter Pharmaceuticals Joins NIH Conference Discussions on Lactose Intolerance and Associated Health Risks
Post Your Comments:
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Care Market by Type (Dressings, Therapy Devices, Active Wound ... Out-Patient Facility), and Geography - Global Forecast to 2020" ... --> --> The purpose of this ... of the global advanced wound care market. It involves ...
(Date:11/26/2015)... 26, 2015 ... "Radioimmunoassay Market by Type (Reagents & ... Academics, Clinical Diagnostic Labs), Application (Research, Clinical ... 2020" report to their offering. ... addition of the "Radioimmunoassay Market by ...
Breaking Medicine Technology:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... potentially more aggressive than those found on mammography, according to a study published ... of additional cancers not seen on mammography may necessitate a change in treatment. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... sauna parts and accessories. , Sauna accessories help improve the bather experience in ... personality. From basic styles for the purist looking for simplicity in design to ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article ... being more and more widely heralded as a breakthrough for performing hernia repairs. The ... over traditional laparoscopic surgery is that it can greatly reduce the pain that a ...
(Date:11/25/2015)... ... ... The McHenry County law firm of Botto Gilbert Lancaster, PC ... Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant David Adcock ... , According to court documents, Adcock testified that on May 10, 2010 he sat ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw YMCA’s student-produced ... in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions for ... years, Brillianteen has been a treasured tradition for numerous families in the Evanston ...
Breaking Medicine News(10 mins):